Yeji
FDA approvalconf 0.75

FDA approval

$SVRA · Savara Inc
Event date
Date TBD
Sponsor runway
18 mo
$202.8M liquid

Evidence

“subject in each case to FDA approval of the Company's MOLBREEVI product candidate for the treatment of aPAP (the "Approval Milestone")”
Source: 8-K filed 2026-01-27View on EDGAR ↗0001193125-26-023378

Comparable historical fda approvals· last 5 years · same event type

100% hit rate (10/10)
TickerDrugDateOutcome
$INCYzynyz2026-05-18success
$INCYjakafi xr2026-05-01success
$AXSMauvelity2026-04-30success
$INCYzynyz2026-03-30success
$BIIBspinraza2026-03-27success
$CORTlifyorli2026-03-25success
$RYTMimcivree2026-03-19success
$ASNDyuviwel2026-02-27success
$BMRNpalynziq2026-02-27success
$ETONdesmoda2026-02-25success

Recent insider activity· ±90 days

1 insider · 0 buys · 0 sells
Exercise
2026-03-18
Lowrance David L
Chief Financial Officer
80,684 @ $1.51$122K
Tax
2026-03-18
Lowrance David L
Chief Financial Officer
24,174 @ $5.04$122K
Exercise
2026-03-18
Lowrance David L
Chief Financial Officer
75,000 @ $1.59$119K
Tax
2026-03-18
Lowrance David L
Chief Financial Officer
23,661 @ $5.04$119K
Exercise
2026-03-18
Lowrance David L
Chief Financial Officer
130,650 @ $1.23$161K
Tax
2026-03-18
Lowrance David L
Chief Financial Officer
31,885 @ $5.04$161K
Exercise
2026-03-18
Lowrance David L
Chief Financial Officer
43,063 @ $1.11$48K
Tax
2026-03-18
Lowrance David L
Chief Financial Officer
9,485 @ $5.04$48K
Exercise
2026-03-18
Lowrance David L
Chief Financial Officer
12,500 @ $4.45$56K
Tax
2026-03-18
Lowrance David L
Chief Financial Officer
11,037 @ $5.04$56K
Exercise
2026-03-18
Lowrance David L
Chief Financial Officer
24,850 @ $3.35$83K
Tax
2026-03-18
Lowrance David L
Chief Financial Officer
16,518 @ $5.04$83K
← All catalysts for $SVRA